Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases

Journal of Urology

Volumn 188, Issue 6, 2012, Pages 2114-2119

  Lee, Cheryl T ^a   Barocas, Daniel ^b   Globe, Denise R ^c   Oefelein, Michael G ^d   Colayco, Danielle C ^c   Bruno, Amanda ^e   O'Day, Ken ^e   Bramley, Thomas ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c ALLERGAN INC   (United States)

^d Genesis Healthcare Partners   (United States)

^e XCENDA   (United States)

Author keywords

administration, intravesical; economics, pharmaceutical; mitomycin; quality adjusted life years; urinary bladder neoplasms

Indexed keywords

MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDICARE; POPULATION RESEARCH; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT CANCER; REIMBURSEMENT; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; COST OF ILLNESS; HUMANS; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84869090013     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.08.005     Document Type: Article

References (21)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. S.F. Altekruse, C.L. Kosary, M. Krapcho et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute Bethesda, MD http://seer.cancer. gov/csr/1975-2007/ based on November 2009 SEER data submission, posted to the SEER web site, 2010
3. A.B. Mariotto, K.R. Yabroff, Y. Shao Projections of the cost of cancer care in the U.S.: 2010-2020 J Natl Cancer Inst 103 2011 117
4. M.F. Botteman, C.L. Pashos, A. Redaelli The health economics of bladder cancer Pharmacoeconomics 21 2003 1315
5. K.D. Sievert, B. Amend, U. Nagele Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295
6. E.B.C. Avritscher, C.D. Cooksley, H.B. Grossman Clinical model of lifetime cost of treating bladder cancer and associated complications Urology 68 2006 549
7. B.B. Reeve, A.L. Potosky, A.W. Smith Impact of cancer on health-related quality of life of older Americans J Natl Cancer Inst 101 2009 860
8. M.F. Botteman, C.L. Pashos, R.S. Hauser Quality of life aspects of bladder cancer: a review of the literature Qual Life Res 12 2003 675
9. C.L. Pashos, M.F. Botteman, B.L. Laskin Bladder cancer: epidemiology, diagnosis, and management Cancer Practice 10 2002 311
10. D.A. Tolley, M.K.B. Parmar, K.M. Grigor The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup J Urol 155 1996 1233
11. R.J. Sylvester, W. Oosterlinck, A.P.M. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186
12. A.M. Nieder, M. Brausi, D. Lamm Management of stage T1 tumors of the bladder: international consensus panel Urology, suppl 66 2005 108
13. Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): 2007 Update Bladder Cancer Clinical Guideline Update Panel 2007 American Urological Association Education and Research Linthicum
14. M. Babjuk, W. Oosterlinck, R. Sylvester Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS) 2009 European Association of Urology Arnhem, The Netherlands
15. R. Madeb, D. Golijanin, K. Noyes Treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence-based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors Cancer 115 2009 2660
16. G.J. Huang, A.S. Hamilton, M. Lo Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the Surveillance, Epidemiology and End Results program 2003 patterns of care project J Urol 180 2008 520
17. J.A. Witjes, K. Hendricksen Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results Eur Urol 53 2008 45
18. Lee C, Gruschkus S, Colayco D, et al. Treatment patterns and costs of treating non-muscle invasive bladder cancer. Presented at annual meeting of Society of Urologic Oncology, Bethesda, Maryland, November 30-December 2, 2011.
19. M.S. Cookson, S.S. Chang, M. Oefelein National practice patterns for immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer J Urol 187 2012 1571
20. G.S. Kulkarni, S.M.H. Alibhai, A. Finelli Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer Cancer 115 2009 5450
21. A. Fiefer, X. Xie, J.M. Brophy Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system Urology 76 2010 652